AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer
Status:
Not yet recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized and open-label phase II study, evaluating the efficacy and
safety of AT vs TP regimen as neoadjuvant treatment for early HER2-negative breast cancer.
Participants will undergo/receive HRD testing after enrollment. HRD-positive patients will be
randomly assigned in a ratio of 1:1 to receive AT（Doxorubicin or Epirubicin+docetaxel）or
TP（Albumin paclitaxel + Cisplatin or Carboplatin）regimen respectively, followed by surgery.
HRD-negative patients will be assigned to receive TP（Albumin paclitaxel + Cisplatin or
Carboplatin）regimen if TNBC, or AT（Doxorubicin or Epirubicin+docetaxel）rigemen, followed by
surgery.